Skip to main content
Top
Published in: Clinical Rheumatology 9/2012

01-09-2012 | Original Article

Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis

Authors: Zhu Chen, Guo-Sheng Wang, Gui-Hong Wang, Xiang-Pei Li

Published in: Clinical Rheumatology | Issue 9/2012

Login to get access

Abstract

The aim of this study is to investigate the association of serum anti-C1q antibody levels with renal pathological characteristics in SLE patients with lupus nephritis. Fifty-two patients with biopsy-proven lupus nephritis were enrolled. Serum anti-C1q levels (units per milliliter) were measured before renal biopsy using ELISA kit. A cross-sectional study analyzed the association of anti-C1q antibody levels with SLE global activity, nephritic activity, and renal histopathology. Thirty-nine of 52 patients (75 %) were positive for anti-C1q antibody. Anti-C1q antibody levels were positively correlated with the values for the SLE Disease Activity Index (r = 0.628, p < 0.001), anti-nucleosome (r = 0.591, p < 0.001), and anti-dsDNA antibody (r = 0.507, p < 0.001), but negatively correlated to serum C3 (r = −0.626, p < 0.001) and C4 (r = −0.57, p < 0.001). The prevalence of anti-C1q in patients with proliferative LN (class III + class IV) was higher than those with mesangial LN (class II), but there is no statistical significance. Among different ISN/RPS classification, serum anti-C1q antibody level was highest in patients with class IV, followed by class III. The concentration of anti-C1q in patients with class IV was higher than those in class II [50.00 (23.00, 97.70) vs 20.25 (7.16, 54.78) U/ml, p<0.05]. The levels of anti-C1q antibody were positively correlated with renal active indices (r = 0.59, p < 0.001) while negatively correlated with chronic indices (r = −0.326, p < 0.05). Moreover, anti-C1q antibody was found to be positively associated with glomerular C1q deposition. These findings indicate that serum anti-C1q antibody is a valuable noninvasive biological marker for prediction of renal histopathology in lupus nephritis. Low or negative anti-C1q antibody titers might influence therapeutic decisions in SLE.
Literature
1.
go back to reference Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997) The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 6(3):290–304PubMedCrossRef Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997) The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 6(3):290–304PubMedCrossRef
3.
go back to reference Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC (1993) Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52(12):851–856PubMedCrossRef Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC (1993) Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52(12):851–856PubMedCrossRef
4.
go back to reference Horvath L, Czirjak L, Fekete B, Jakab L, Pozsonyi T, Kalabay L, Romics L, Miklos K, Varga L, Prohaszka Z, Szakacs A, Nagy E, Daha MR, Fust G (2001) High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 19(6):667–672PubMed Horvath L, Czirjak L, Fekete B, Jakab L, Pozsonyi T, Kalabay L, Romics L, Miklos K, Varga L, Prohaszka Z, Szakacs A, Nagy E, Daha MR, Fust G (2001) High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 19(6):667–672PubMed
5.
go back to reference Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA (2005) Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64(3):444–448PubMedCrossRef Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA (2005) Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64(3):444–448PubMedCrossRef
6.
go back to reference Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH (2009) Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant 24(1):172–178PubMedCrossRef Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH (2009) Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant 24(1):172–178PubMedCrossRef
7.
go back to reference Zhang CQ, Ren L, Gao F, Mu FY, You YQ, Liu YH (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clin Rheumatol 30(7):967–973PubMedCrossRef Zhang CQ, Ren L, Gao F, Mu FY, You YQ, Liu YH (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clin Rheumatol 30(7):967–973PubMedCrossRef
8.
go back to reference Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH (2002) Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J Rheumatol 29(4):693–699PubMed Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH (2002) Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J Rheumatol 29(4):693–699PubMed
9.
go back to reference Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37(3):490–498PubMedCrossRef Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G, Schifferli JA, Meroni PL, Ponticelli C (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37(3):490–498PubMedCrossRef
10.
go back to reference Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, Tesar V, Sadallah S, Schifferli J (2006) High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 21(11):3115–3121PubMedCrossRef Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, Tesar V, Sadallah S, Schifferli J (2006) High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 21(11):3115–3121PubMedCrossRef
11.
go back to reference Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G, Dieude P, Chollet-Martin S (2009) Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 11(3):R87PubMedCrossRef Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G, Dieude P, Chollet-Martin S (2009) Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 11(3):R87PubMedCrossRef
12.
go back to reference Cai X, Yang X, Lian F, Lin X, Liang M, Li J, Chen X, Liang L, Qin S, Fu J (2010) Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol 37(4):759–765PubMedCrossRef Cai X, Yang X, Lian F, Lin X, Liang M, Li J, Chen X, Liang L, Qin S, Fu J (2010) Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol 37(4):759–765PubMedCrossRef
13.
go back to reference Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, Fabien N (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20(1):28–34PubMedCrossRef Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, Fabien N (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20(1):28–34PubMedCrossRef
14.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRef
15.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRef
16.
go back to reference Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521–530PubMedCrossRef Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521–530PubMedCrossRef
17.
go back to reference Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25(4):689–695PubMedCrossRef Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25(4):689–695PubMedCrossRef
18.
go back to reference Trendelenburg M (2005) Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 27(3):276–285PubMedCrossRef Trendelenburg M (2005) Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 27(3):276–285PubMedCrossRef
21.
go back to reference Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G (2009) Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 1173:47–51PubMedCrossRef Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G (2009) Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 1173:47–51PubMedCrossRef
22.
go back to reference Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, Baba S, Hara M, Yamanaka H (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 63(8):2436–2444PubMedCrossRef Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, Baba S, Hara M, Yamanaka H (2011) Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 63(8):2436–2444PubMedCrossRef
23.
go back to reference Ronnelid J, Huang YH, Norrlander T, Rogberg S, Nilsson B, Gustafsson R, Klareskog L (1994) Short-term kinetics of the humoral anti-C1q response in SLE using the ELISPOT method: fast decline in production in response to steroids. Scand J Immunol 40(2):243–250PubMedCrossRef Ronnelid J, Huang YH, Norrlander T, Rogberg S, Nilsson B, Gustafsson R, Klareskog L (1994) Short-term kinetics of the humoral anti-C1q response in SLE using the ELISPOT method: fast decline in production in response to steroids. Scand J Immunol 40(2):243–250PubMedCrossRef
24.
go back to reference Trouw LA, Daha MR (2005) Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 5(2):243–251PubMedCrossRef Trouw LA, Daha MR (2005) Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 5(2):243–251PubMedCrossRef
25.
go back to reference Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132(1):32–39PubMedCrossRef Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132(1):32–39PubMedCrossRef
26.
go back to reference Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114(5):679–688PubMed Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114(5):679–688PubMed
27.
go back to reference Mannik M, Wener MH (1997) Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 40(8):1504–1511PubMedCrossRef Mannik M, Wener MH (1997) Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 40(8):1504–1511PubMedCrossRef
28.
go back to reference Chen PC, Wang CR, Liu MF, Chen FF, Liang CC (2002) Correlation between the renal C1q deposition and serum anti-C1q antibody: a potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol 20(4):223–227PubMed Chen PC, Wang CR, Liu MF, Chen FF, Liang CC (2002) Correlation between the renal C1q deposition and serum anti-C1q antibody: a potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol 20(4):223–227PubMed
Metadata
Title
Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis
Authors
Zhu Chen
Guo-Sheng Wang
Gui-Hong Wang
Xiang-Pei Li
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2017-1

Other articles of this Issue 9/2012

Clinical Rheumatology 9/2012 Go to the issue

Letter to the Editor

Response to Schwerla

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine